Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Use of Neostigmine in Sepsis and Septic Shock.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-85 years.~* Patients diagnosed with sepsis or septic shock according to Third International Consensus Definitions for Sepsis and Septic Shock mentioned above.~* Patients who have ≥ 2 of the following four criteria plus documented infection:~  1. Fever ≥ 38 °C or hypothermia ≤ 36 °C.~ 2. Tachycardia ≥ 100/min.~ 3. Tachypnea ≥ 20/min or hyperventilation.~ 4. Leukocytosis ≥ 12000/mm3 or leukopenia ≤ 4000/mm3 or ≥ 10% immature neutrophils in the differential count.~Exclusion criteria:~* Known hypersensitivity to choline esterase inhibitors.~* Known absolute contra-indications against choline esterase inhibitors such as, myotonic dystrophy; depolarization block by depolarizing muscle relaxants; intoxication by irreversibly acting cholinesterase inhibitors; closed craniocerebral trauma; obstruction in the gastrointestinal tract (mechanical constipation); obstruction in the urinary tract (mechanical urinary retention)~* Known relative contraindications against choline esterase inhibitors: bronchial asthma; bradycardia; AV-conduction disturbances.~* Having undergone solid organ transplantation.~* Pregnant and lactating women.~* Participation in another clinical trial.~* Presence of primary or concomitant illness, impending death.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Neostigmine group (Type: EXPERIMENTAL): This arm will receive -in addition to standard therapy for sepsis and septic shock-Neostigmine methylsulfate ampoule diluted in normal saline, and administered as continuous infusion for five days. The rate of infusion is 0.2 mg/hr.
- Standard group (Type: PLACEBO_COMPARATOR): This arm will receive the standard therapy for sepsis and septic shock only and followed for five days.

Based on this trial design, predict the completion outcome and termination type (if applicable).